Dr. Jiagge's overall goal is to identify new and improved modalities of screening, diagnosis, and treatment of breast cancer in order to improve the outcomes for women with African ancestry. Her lab has already developed a collaboration with nine institutions in Africa (Ghana and Tanzania), and with the University of Michigan, toaccess breast tumors from diverse ethnicities. She will coordinate scientific activities, including experimental planning and protocol design as well as data analysis and manuscript preparation.

Dr. Jiagge is a physician scientist with a background in the molecular and genetic basis of aggressive breast cancer. In her surgical and medical studies at the Kwame Nkrumah University of Science and Technology, she observed that Ghanaian breast cancer patients performed poorly; i.e., had rapid progression and high mortality rates. Due to the lack of population-based cancer registries and limited data defining the tumour biology of individual patients, the extent of the disease has not been accurately reported, and little effort is put into identifying new and improved modalities of treatment.

Her PhD studies at the University of Michigan inspired her to focus on cancer biology and stem cell research with an emphasis on the relationship of ethnic differentiation with triple negative breast cancer (TNBC). She currently leads the Jiagge Lab at the Henry Ford Cancer Institute, and is an adjunct Research Investigator at the University of Michigan. Dr. Jiagge has contributed to, and led, over 30 papers and abstracts. She has most recently directed and developed the Precision Medicine for Aggressive/African BreastCancer (PMABC), an international collaboration through the HFHS of nine different partner institutions in East and West Africa. To further the efforts of developing treatment for TNBC, PMABC aims to create a channel for patient data/samples to be shared.